EYA3 is closely associated with tumor progression and low levels of treatment success (Vartuli et al., 2018), and interacts with cellular inhibitor of PP2A (PP2A) to increase the stability of c-Myc, thus promoting tumor development (Zhang et al., 2018). Here, MYC is linked to neoplasm.